The semen analysis market size is valued at USD 350.0 million in 2021 and is poised to grow at a significant CAGR of 8.0% over 2022–2028. Male factor infertility constitutes the majority of the increase in infertility cases and is an essential driver of the semen analysis industry. According to WHO multicenter studies, a substantial percentage of infertility is linked to the male partner’s reproductive abnormalities or illnesses. Also, one out of every four couples in developing nations has infertility, and it has been estimated that more than 50 million people have infertility. There is an increasing demand for semen analysis, which helps to determine the health, quality, and viability of sperm. In addition, the test will reveal if infertility is caused by a low sperm count or sperm malfunction. Furthermore, the availability of technologically advanced product offerings will create further prospects for the semen analysis market to flourish in the future years. Microscopy, chromatographic immunoassay, colorimetric reaction, and smartphone-based testing have all helped the healthcare business fulfill the needs of the new generation of patients. The demand for assisted reproductive technologies (ARTs) has altered growth dynamics beneficially. In the semen analysis market, manufacturers are focused on enhancing the accuracy of sperm quality assessment, which helps to address patients’ evolving needs. The prospects have been enhanced by a growing grasp of specimen needs and procedures. The availability of improved smartphone-enabled testing in industrialized countries has boosted the market growth. The value chain of stakeholders has been enriched by the increasing number of fertility clinics in developed and developing economies. The rise in funding and supportive government initiatives across various countries is anticipated to boost the adoption of fertility treatments. The Singapore government offers around 75% co-funding for different Assisted Reproductive Technology (ART) procedures, such as IVF, Gamete Intrafallopian Transfer (GIFT), and Intracytoplasmic Sperm Injection (ICSI).
Recent Market Developments:
In July 2021, Halotech participated in the catalogue of ANACER – National Association of Assisted Reproduction Clinics – highlighting the importance of the DNA fragmentation test.